Literature DB >> 10321934

Molecular mechanisms of action of bisphosphonates.

M J Rogers1, J C Frith, S P Luckman, F P Coxon, H L Benford, J Mönkkönen, S Auriola, K M Chilton, R G Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10321934     DOI： 10.1016/s8756-3282(99)00070-8

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


× No keyword cloud information.
  46 in total

Review 1.  Direct antitumour activity of zoledronic acid: preclinical and clinical data.

Authors:  Joaquim Bosch-Barrera; Sofía D Merajver; Javier A Menéndez; Catherine Van Poznak
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

2.  The effects of bisphosphonates on osteonecrosis of jaw bone: a stem cell perspective.

Authors:  Hüseyin Abdik; Ezgi Avşar Abdik; Selami Demirci; Ayşegül Doğan; Duygu Turan; Fikrettin Şahin
Journal:  Mol Biol Rep       Date:  2018-12-01       Impact factor: 2.316

Review 3.  [Bisphosphonates in oncology].

Authors:  A A Kurth; A Heidenreich; I Diel
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 4.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

5.  Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.

Authors:  Valeria S Rosso; Sergio H Szajnman; Leena Malayil; Melina Galizzi; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Bioorg Med Chem       Date:  2011-04-01       Impact factor: 3.641

6.  Pamidronate treatment improves bone mineral density in children with Menkes disease.

Authors:  S Kanumakala; A Boneh; M Zacharin
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

7.  Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up.

Authors:  Philipp Stockmann; Eleftherios Vairaktaris; Falk Wehrhan; Martin Seiss; Stephan Schwarz; Bernd Spriewald; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Support Care Cancer       Date:  2009-07-17       Impact factor: 3.603

8.  Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite.

Authors:  Sanjeev J Suratwala; Samuel K Cho; Jonathan J van Raalte; Sang Hyun Park; Sung Wook Seo; Seong-Sil Chang; Thomas R Gardner; Francis Young-In Lee
Journal:  J Bone Joint Surg Am       Date:  2008-10       Impact factor: 5.284

9.  Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato; Mitsuyoshi Uzawa
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

10.  Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis.

Authors:  Jun Iwamoto; Mitsuyoshi Uzawa; Yoshihiro Sato; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.